In kidney transplant recipients, there is discordance between the development of cellular and humoral response after vaccination against SARS-CoV-2. We sought to determine the interplay between the 2 arms of adaptive immunity in a 3-dose course of mRNA-1273 100 μg vaccine. Methods: Humoral (IgG/IgM) and cellular (N- and S-ELISpot) responses were studied in 117 kidney and 12 kidney-pancreas transplant recipients at the following time points: before the first dose, 14 d after the second dose' and before and after the third dose, with a median of 203 and 232 d after the start of the vaccination cycle, respectively. Results: After the second dose, 26.7% of naive cases experienced seroconversion. Before the third dose and in the absence of COVID-19, this percentage increased to 61.9%. After the third dose, seroconversion occurred in 80.0% of patients. Naive patients who had at any time point a detectable positivity for S-ELISpot were 75.2% of the population, whereas patients who maintained S-ELISpot positivity throughout the study were 34.3%. S-ELISpot positivity at 42 d was associated with final seroconversion (odds ratio' 3.14; 95% confidence interval' 1.10-8.96; P = 0.032). Final IgG titer was significantly higher in patients with constant S-ELISpot positivity (P < 0.001). Conclusions: A substantial proportion of kidney transplant recipients developed late seroconversion after 2 doses. Cellular immunity was associated with the development of a stronger humoral response.
In kidney transplant recipients, there is discordance between the development of cellular and humoral response after vaccination against SARS-CoV-2. We sought to determine the interplay between the 2 arms of adaptive immunity in a 3-dose course of mRNA-1273 100 μg vaccine. Methods: Humoral (IgG/IgM) and cellular (N- and S-ELISpot) responses were studied in 117 kidney and 12 kidney-pancreas transplant recipients at the following time points: before the first dose, 14 d after the second dose' and before and after the third dose, with a median of 203 and 232 d after the start of the vaccination cycle, respectively. Results: After the second dose, 26.7% of naive cases experienced seroconversion. Before the third dose and in the absence of COVID-19, this percentage increased to 61.9%. After the third dose, seroconversion occurred in 80.0% of patients. Naive patients who had at any time point a detectable positivity for S-ELISpot were 75.2% of the population, whereas patients who maintained S-ELISpot positivity throughout the study were 34.3%. S-ELISpot positivity at 42 d was associated with final seroconversion (odds ratio' 3.14; 95% confidence interval' 1.10-8.96; P = 0.032). Final IgG titer was significantly higher in patients with constant S-ELISpot positivity (P < 0.001). Conclusions: A substantial proportion of kidney transplant recipients developed late seroconversion after 2 doses. Cellular immunity was associated with the development of a stronger humoral response.
Authors: Mark M Painter; Divij Mathew; Rishi R Goel; Sokratis A Apostolidis; Ajinkya Pattekar; Oliva Kuthuru; Amy E Baxter; Ramin S Herati; Derek A Oldridge; Sigrid Gouma; Philip Hicks; Sarah Dysinger; Kendall A Lundgreen; Leticia Kuri-Cervantes; Sharon Adamski; Amanda Hicks; Scott Korte; Josephine R Giles; Madison E Weirick; Christopher M McAllister; Jeanette Dougherty; Sherea Long; Kurt D'Andrea; Jacob T Hamilton; Michael R Betts; Paul Bates; Scott E Hensley; Alba Grifoni; Daniela Weiskopf; Alessandro Sette; Allison R Greenplate; E John Wherry Journal: Immunity Date: 2021-08-13 Impact factor: 43.474
Authors: David Cucchiari; Natalia Egri; Marta Bodro; Sabina Herrera; Jimena Del Risco-Zevallos; Joaquim Casals-Urquiza; Frederic Cofan; Asunción Moreno; Jordi Rovira; Elisenda Banon-Maneus; Maria J Ramirez-Bajo; Pedro Ventura-Aguiar; Anna Pérez-Olmos; Marta Garcia-Pascual; Mariona Pascal; Anna Vilella; Antoni Trilla; José Ríos; Eduard Palou; Manel Juan; Beatriu Bayés; Fritz Diekmann Journal: Am J Transplant Date: 2021-08-04 Impact factor: 9.369
Authors: Lisa A Jackson; Evan J Anderson; Nadine G Rouphael; Paul C Roberts; Mamodikoe Makhene; Rhea N Coler; Michele P McCullough; James D Chappell; Mark R Denison; Laura J Stevens; Andrea J Pruijssers; Adrian McDermott; Britta Flach; Nicole A Doria-Rose; Kizzmekia S Corbett; Kaitlyn M Morabito; Sijy O'Dell; Stephen D Schmidt; Phillip A Swanson; Marcelino Padilla; John R Mascola; Kathleen M Neuzil; Hamilton Bennett; Wellington Sun; Etza Peters; Mat Makowski; Jim Albert; Kaitlyn Cross; Wendy Buchanan; Rhonda Pikaart-Tautges; Julie E Ledgerwood; Barney S Graham; John H Beigel Journal: N Engl J Med Date: 2020-07-14 Impact factor: 91.245
Authors: Teresa Lambe; Andrew J Pollard; Merryn Voysey; Shuo Feng; Daniel J Phillips; Thomas White; Homesh Sayal; Parvinder K Aley; Sagida Bibi; Christina Dold; Michelle Fuskova; Sarah C Gilbert; Ian Hirsch; Holly E Humphries; Brett Jepson; Elizabeth J Kelly; Emma Plested; Kathryn Shoemaker; Kelly M Thomas; Johan Vekemans; Tonya L Villafana Journal: Nat Med Date: 2021-09-29 Impact factor: 53.440